ADC Linker Design Service
ADC linker is one of the three main components of antibody-drug conjugates (ADCs), connecting antibodies to effective drugs through chemical bonds. The ADC linker design service provided by CD ComputaBio is an essential step in the development of antibody-drug conjugates (ADCs). As a bridge between the antibody and its payload, the linker has a crucial impact on the performance and safety of ADCs.
Introduction to ADC Linker
ADC linkers play a key role in determining the overall success of antibody-drug conjugates. One of the major challenges in developing safe and effective ADC drugs. Well-designed ADC linkers can help antibodies selectively deliver and accurately release cytotoxic drugs at tumor sites. Stable ADC drugs ensure that less cytotoxic payloads are shed before reaching tumor cells, thereby improving safety and limiting dosage.
Computational Design of ADC Linker
Computational design has changed the process of ADC linker development. By leveraging advanced algorithms and simulations, it can quickly analyze a large library of potential linker structures while taking into account factors such as antibody structure to enhance the efficacy and safety of ADCs and accelerate the development of more effective ADC therapies.
Figure 1. The structure an ADC drug. (Wittwer N L, et al., 2023)
Our Services
CD ComputaBio is able to provide advanced algorithms and technology platforms for ADC linker design services. Our expert team has extensive experience in ADC drug design, and the services we provide include but are not limited to:
Cleavable Linker Design Service
Cleavable Linkers is a class of conjugation linker, which can connect two or more molecules together. Our cleavable linker design service utilizes advanced computational tools to design linkers that cleave under specific conditions. We design to enhance therapeutic efficacy while minimizing off-target effects.
Non-cleavable Linkers Design Service
Non-cleavable linkers are an important tool in antibody-drug conjugate (ADC) discovery. The advantage of non-cleavable linkers is the ability to modulate the activity of metabolites. Using computational chemistry and molecular modeling, we optimized the structure of the non-cleavable linker to maintain a strong bond between the antibody and the payload.
Site-Specific Linker Design Service
Site-Specific linkers offer precise coupling of cytotoxins or chemotherapeutic drugs to specific sites within antibody molecules. They ensure ADCs exhibit high homogeneity and an increased therapeutic index. CD ComputaBio provides site-specific linker design services, our computational platform analyzes the structure of antibodies at the atomic level to determine the ideal attachment site for the linker.
Advanced Methods for ADC Linker Design
CD ComputaBio provides advanced ADC linker design to meet the various needs of our customers. These methods are designed to handle molecules with various ADC drugs:
- De Novo Design
- Fragment-based Drug Design
- Structure-based Drug Design
- Ligand-based Drug Design
- AI-based Drug Design
- More
Advantages
Technology Innovations
CD ComputaBio uses in-house computational algorithms and software for ADC linker design. Our design model can accurately predict how linker changes affect ADC stability and drug-release. This technology helps us explore new linker chemistries, offering clients advanced design solutions.
Tailored Service Model
Each ADC project is different. Our team offers customized solutions, from initial analysis of antibody-payload combinations and project goals to final implementation. We also adjust our design process according to budget, timeline, and regulatory needs, ensuring clients get the best value.
Robust Data Security
Data security is crucial in pharmaceutical research. CD ComputaBio has a multi-layer security system for client data. Our platforms use top-level encryption for data transfer and storage. Only authorized staff can access data, and we regularly audit and assess system vulnerabilities.
CD ComputaBio provides high-quality ADC linker design, including different types of linker designs. Our experienced chemists and computational experts use a range of techniques and algorithms to optimize ADC linker design. If you are interested in our services or have any questions, please feel free to contact us.
Reference:
- Wittwer N L, Brown M P, Liapis V, et al. Antibody drug conjugates: hitting the mark in pancreatic cancer? Journal of Experimental & Clinical Cancer Research, 2023, 42(1): 280.
* For Research Use Only.
Related Services
